⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161507 | 0.69 | — | — | |
| SCHEMBL5405236 | 0.67 | — | — | |
| SCHEMBL17826992 | 0.65 | TRIM24 (0.41) | — | |
| SCHEMBL22590610 | 0.65 | — | — | |
| SCHEMBL677601 | 0.65 | — | — | |
| SCHEMBL16321152 | 0.65 | — | — | |
| SCHEMBL123412 | 0.65 | — | — | |
| SCHEMBL18607308 | 0.63 | — | — | |
| Water SCHEMBL2873089 | 0.63 | — | — | |
| SCHEMBL10239513 | 0.61 | GAA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009772-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2018-01-11 | — | — | US | claimed |
| US-20150344448-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2015-12-03 | — | — | US | claimed |
| WO-2014116594-A1 | HIGHLY SELECTIVE ANTI-CANCER AGENTS TARGETING NON-SMALL CELL LUNG CANCER AND OTHER FORMS OF CANCER | THE UNIVERSITY OF TOLEDO (US) | 2014-07-31 | — | — | WO | claimed |
| CN-107027306-B | 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea derivatives as CXCR2 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10392354-B2 | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | THE UNIVERSITY OF TOLEDO (US) | 2019-08-27 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20190023671-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190010135-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10138216-B2 | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | THE UNIVERSITY OF TOLEDO (US) | 2018-11-27 | — | — | US | disclosed |
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3148963-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015031824-A9 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344448-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2015-12-03 | — | — | US | disclosed |
| WO-2015031824-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014116594-A1 | HIGHLY SELECTIVE ANTI-CANCER AGENTS TARGETING NON-SMALL CELL LUNG CANCER AND OTHER FORMS OF CANCER | THE UNIVERSITY OF TOLEDO (US) | 2014-07-31 | — | — | WO | disclosed |